Frontier Medicines

An artists illustration of a KRAS G12C mutation in non-small cell lung cancer

Research

AACR: KRAS inhibitors pop in preclinical data debuts

Verastem Oncology, Quanta Therapeutics, Frontier Medicines and more showed off new preclinical data on drugs against the once-”undruggable” target.

Helen Floersh Apr 11, 2024 4:30am

Palm tree branches bending as storm clouds approach

Frontier CEO weathers one of his hardest fundraises to add $80M

Feb 22, 2024 4:01pm

race runners running sprint marathon catch up

Next round of KRAS drugs follow footsteps of Amgen and Mirati

May 4, 2023 6:00am

parachute chutes

Billy Dunn departs FDA—Chutes & Ladders

Mar 3, 2023 9:30am

AbbVie pays Frontier $55M to pursue hard-to-drug targets

Dec 3, 2020 8:05am

Frontier bolsters leadership team with new CSO, tech hires

Jul 31, 2019 9:50am